Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;72(2):313-328.
doi: 10.1007/s00011-022-01674-z. Epub 2022 Dec 20.

The star target in SLE: IL-17

Yi Yang  1 , Chen Yan  1 , Le Yu  1 , Xiuling Zhang  1 , Jingjing Shang  1 , Jie Fan  1 , Rongwei Zhang  1 , Jie Ren  1 , Xinwang Duan  2
Affiliations
Review

The star target in SLE: IL-17

Yi Yang et al. Inflamm Res. 2023 Feb.

Abstract

Purpose: The purpose of this review is to discuss the significance of IL-17 in SLE and the potential of IL-17-targeted therapy.

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect many organs and tissues throughout the body. It is characterized by overactive B and T cells and loss of immune tolerance to autoantigens. Interleukin-17 (IL-17) is a cytokine that promotes inflammation and has been implicated in the pathogenesis of several autoimmune diseases as well as inflammatory diseases. In in vitro cellular experiments in lupus susceptible mice or SLE patients, there is substantial evidence that IL-17 is a highly promising therapeutic target.

Methods: We searched papers from PubMed database using the search terms, such as interleukin-17, systemic lupus erythematosus, treatment targets, T cells, lupus nephritis, and other relevant terms.

Results: We discuss in this paper the molecular mechanisms of IL-17 expression, Th17 cell proliferation, and the relationship between IL-17 and Th17. The significance of IL-17 in SLE and the potential of IL-17-targeted therapy are further discussed in detail.

Conclusion: IL-17 has a very high potential for the development as a star target in SLE.

Keywords: Interleukin-17; Lupus nephritis; Systemic lupus erythematosus; T cells; Treatment targets.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med. 2020;172:ITC1–96. - DOI
    1. Lim SS, Helmick CG, Bao G, Hootman J, Bayakly R, Gordon C, et al. Racial disparities in mortality associated with systemic lupus erythematosus—Fulton and DeKalb Counties, Georgia, 2002–2016. MMWR Morb Mortal Wkly Rep. 2019;68:419–22. - PubMed - PMC - DOI
    1. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2020;80:14–25. - PubMed - DOI
    1. Sánchez ARP, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol. 2022;18:146–57. - DOI
    1. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang Y-H, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133–41. - PubMed - PMC - DOI

LinkOut - more resources